Earnings Summary

Entrada Therapeutics, Inc.’s revenue jumped +Inf% since last year same period to $18.17Mn in the Q2 2023. On a quarterly growth basis, Entrada Therapeutics, Inc. has generated -28.07% fall in its revenue since last 3-months.

Entrada Therapeutics, Inc.’s net profit fell -11.86% since last year same period to $-25.93Mn in the Q2 2023. On a quarterly growth basis, Entrada Therapeutics, Inc. has generated -6157.94% fall in its net profits since last 3-months.

Entrada Therapeutics, Inc.’s net profit margin jumped NaN% since last year same period to -142.7% in the Q2 2023. On a quarterly growth basis, Entrada Therapeutics, Inc. has generated -8521.78% fall in its net profit margins since last 3-months.

Entrada Therapeutics, Inc.’s earning per share (EPS) estimates for the current quarter stand at -0.91 - a -35.1% fall from last quarter’s estimates.

Entrada Therapeutics, Inc.’s earning per share (EPS) estimates for the current year stand at -0.91.

Entrada Therapeutics, Inc.’s earning per share (EPS) jumped 100% since last year same period to 0 in the Q3 2023. This indicates that the Entrada Therapeutics, Inc. has generated 100% annual rate of jump in its earning per share (EPS) in the last 4 quarters.